MedTrace Logo

A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan

NCT06629857 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2024-10-08

No results posted yet for this study

Summary

This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC). The goal is to determine whether AFP levels vary based on the size of the liver tumor or other health conditions like hepatitis B, hepatitis C, and obesity. By analyzing data from 94 patients, the study seeks to identify factors that influence AFP levels, which may help in understanding liver cancer progression and improving diagnosis and treatment approaches.

Conditions

  • Carcinoma, Hepatocellular

Sponsors & Collaborators

  • Darul Sehat Hospital

    lead OTHER

Eligibility

Min Age
27 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-30
Primary Completion
2023-03-01
Completion
2023-03-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06629857 on ClinicalTrials.gov